Kun Tuo will lay emphasis on the development of customized solutions to help local and global biopharma companies achieve registration of new medicines in China.
In addition the CRO will also provide a portfolio of services, including comprehensive clinical trial management, regulatory submission preparation, biostatistics and data management.
Kun Tuo is believed to make use of Quintiles’ global resources and expertise to develop customized offerings in key therapeutic areas, besides vaccines, late phase studies, medical devices and diagnostics.